News

Biotechs raise money from the crowd
Enlarge image

EU

Biotechs raise money from the crowd

04.09.2015 - Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

European life science companies are increasingly interested in using crowdfinancing as an additional financing instrument. In Europe, a total of 18 equity-based platforms can be identified as being the most relevant for life science companies. Between 2010 and June 2015, 42 life science companies successfully finished a campaign, bringing the total capital raised through crowdfinancing in Europe to almost €23m. These are the main findings of the “Analysis of Crowd-based Financing in European Life Sciences”, published on the occasion of the “Crowd Dialog Europe 2015” in Helsinki by German market analyst BIOCOM AG.  

A survey among the readers of European Biotechnology Magazine also reveals that the life science community is optimistic with respect to the future of crowdfinancing. 50% of the people say that crowdfinancing will become a relevant financing instrument for the life sciences, a further 28% think it is not yet the right time. 

“With respect to the high capital demand in the life sciences, it was only a question of time before firms jumped on the bandwagon of crowdfinancing”, says Sandra Wirsching, researcher at Berlin-based BIOCOM AG. According to the analysis, the last two years in particular have seen a specific dynamic. In 2014, the number of life science related crowdfinancing campaigns on the 18 analysed platforms increased to 18, twice as many as in 2013. By June 2015 alone, a total of 13 European life science companies had already opted for this alternative financing instrument. 

As demonstrated within the analysis, the average amount per life science campaign was about €550,000. Ten biotech and medtech companies succeeded in raising around €1m or more in capital. Moreover, in 2014 and 2015, a new trend in the European crowdfinancing market emerged: the specialisation of platforms towards life sciences. According to the report, there are four European platforms with a health or life science focus. 

In its conclusion, the report underlines high dynamics and a growing professionalism, which has been observed in the crowdfinancing market in recent years. “Platform operators more often cooperate with professional investors and VC capitalists, making also higher amounts of capital available for the firms”, Wirsching concludes. In addition, the legal background in most of the European countries has also improved. Here, the report includes an overview by legal experts from Dentons Europe, outlining the main characteristics of the legal environment in the most important European countries and in the US. 

More information is available here: www.biocom.de/en/crowdfinancing2015

http://www.european-biotechnology-news.com/news/news/2015-04/biotechs-raise-money-from-the-crowd.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html?cHash=807fa298e991d514ff878d4f7a870d11&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SAREUM HOLDINGS (UK)0.26 GBP18.18%
  • EVOCUTIS (UK)0.19 GBP5.56%
  • CERENIS THERAPEUTICS HOLDING SA (F)13.43 EUR5.09%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • 4SC (D)3.17 EUR-8.12%
  • STALLERGENES (F)47.02 EUR-6.07%

TOP

  • KARO BIO (S)41.10 SEK2375.9%
  • BIOTECH PHARMACON (N)16.10 NOK69.5%
  • TIGENIX (B)1.18 EUR66.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.30 SEK-48.6%
  • THROMBOGENICS (B)2.85 EUR-43.0%

TOP

  • KARO BIO (S)41.10 SEK4570.5%
  • ADOCIA (F)87.80 EUR425.4%
  • GALAPAGOS (B)51.42 EUR315.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.30 SEK-82.3%
  • BIOTEST (D)19.82 EUR-77.1%

No liability assumed, Date: 04.09.2015